Citations

Clear

163 citation(s) found for "Sharp, H L".

Molecular landscape of prostate cancers with clival metastases
Likasitwatanakul, Pornlada , Blinka, Steven , Zarka, Jabra , Gebrael, Georges , Weg, Emily S. , Longoria, Ossian , Moore, Joseph A , Sharp, Adam , Bono, Johann de, Sternberg, Cora N, Agarwal, Neeraj, Swami, Umang , Orme, Jacob J. , Schweizer, Michael T. , Hwang, Justin H, Antonarakis, Emmanuel S, Bono, Johann S. de , Antonarakis, Emmanuel S. , Hwang, Justin H. , Gebrael, Georges , Antonarakis, Emmanuel S. , Blinka, Steven M , Zarka, Jabra G , Weg, Emily , de Bono, Johann , Agarwal, Archana M , Sloan, Lindsey , Hwang, Justin H , Antonarakis, Emmanuel S , Antonarakis, Emmanuel S , Sternberg, Cora N , Agarwal, Neeraj

Mayo Clinic

The Oncologist | March 1, 2026 | Volume: 31 | Issue: 4 | Pages: No page available

10.1093/oncolo/oyag074 | PMID 41782345 Get It

Abstract Background Clival metastases are a rare and clinically aggressive manifestation of advanced prostate cancer, associated with cranial nerve palsy and poor survival. The molecular features of prostate cancers giving rise to clivus metastases remain unknown. Patients and methods We performed a multi-center retrospective study across six institutions, identifying prostate cancer patients with radiographically confirmed clival metastases and available next-generation sequencing (NGS) data. Baseline characteristics and clinical outcomes were collected. Genomic alterations from tissue- and/or blood-based assays were aggregated at the patient level and compared with a publicly available metastatic castration-resistant prostate cancer (mCRPC) cohort (SU2C/PCF). Results Fifty-nine patients with clival metastases contributed 87 molecular assays. More than half of patients had Gleason grade group 5 cancer and presented with de novo metastatic (M1) disease. The median interval from initial prostate cancer diagnosis to clival metastasis was 71.4 months (95% CI, 42.0-101.7), while median overall survival following clival involvement was only 15.3 months (95% CI, 6.9-22.8). Compared with the SU2C/PCF mCRPC cohort, clival metastases showed significant enrichment of BRAF and CHEK2 alterations as well as homologous recombination repair (HRR) with relative depletion of AR-related, PI3K pathway, and G2–M pathway alterations. Conclusion Prostate cancers giving rise to clival metastases exhibit a distinct molecular profile enriched for DNA damage–repair and RAF kinase alterations, suggesting unique metastatic biology and potential therapeutic vulnerabilities.
Association Between Surgical Robotic Availability and Open Operation Rate: A Geographic Analysis
Anderson, Charles K, Wall-Wieler, Elizabeth, Fazal, Zahra , Sahai, Nikhil, Hoeler, Don, Lee, Pamela C, Ven Fong, Zhi, Fong, Zhi Ven , Wall‐Wieler, Elizabeth , Mitzman, Brian

Mayo Clinic

Journal of the American College of Surgeons | February 9, 2026 | Volume: 243 | Issue: 1 | Pages: 193-200

10.1097/xcs.0000000000001837 | PMID 41660858 Get It

BACKGROUND: Despite the widespread adoption of minimally invasive surgery in the US, disparities in its use persist. One unexplored contributor is geographic access to robotic surgical systems. This study evaluates the geospatial association between: (1) Social Vulnerability Index (SVI) and open surgery rates, (2) availability of robotic systems and open surgery, and (3) open surgery rates in demographically similar areas with differing robotic access. STUDY DESIGN: Data from 6 sources were linked at the ZIP Code Tabulation Area (ZCTA) level to identify hospitals and to extract procedure modality, presence of robotic systems, and area characteristics. Regression analysis assessed the association between SVI and open surgery rates. Open rates were then compared between hospitals with and without robotic systems. Propensity score matching was used to compare open rates across matched ZCTAs by robotic access and SVI levels. RESULTS: Higher social vulnerability was associated with increased open surgery rates (estimate = 0.20; p < 0.01), with rates ranging from 18.3% in low-vulnerability areas to 32.7% in high-vulnerability areas. Among 3,446 eligible ZCTAs, 57% had at least 1 robotic system. ZCTAs without robotic systems had higher open surgery rates (42.9 vs 19.4 per 100 procedures; relative rate = 2.21; p < 0.01). This association remained significant after matching (relative rate = 1.66; p < 0.01), for the low-mid- and high-SVI strata, and 3 of the 5 procedures examined. CONCLUSIONS: When correcting for geographic variation, the availability of robotic surgery was associated with a decrease in open surgery rates.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, Clifford R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Qi, Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Chiotis, Konstantinos, Rabinovici, Gil D., Rosa‐Neto, Pedro, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew W., Whittington, Alex , Carrillo, M., Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Stephenson, Diane , Tatton, Nadine , Brendel, Matthias, Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald C. , Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Smith, Ruben, Stephens, Andrew W., Carrillo, María C. , Kolb, Hartmuth C. , Brendel, Matthias , Xie, Fang , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106362 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [ 18 F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [ 18 F]flortaucipir (ADNI), [ 18 F]MK‐6240 (CPAS), and [ 18 F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([ 18 F]flortaucipir) and AIBL ([ 18 F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [ 18 F]flortaucipir and [ 18 F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([ 18 F]PI‐2620) are underway.
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
Alderuccio, Juan Pablo , Baggio, Diva , Han, Sunwoo , Nizamuddin, Imran , Saha, Aditi, Dong, Ning , Wang, Yucai, Cherng, Hua‐Jay J. , Wagner-Johnston, Nina D., Desai, Amrita, Geethakumari, Praveen Ramakrishnan , Moyo, Tamara K. , Sandoval‐Sus, Jose , EPPERLA, NARENDRANATH, Kamdar, Manali, Tavarozzi, Rita , Danilov, A., Tun, H., Munoz, Javier, Narkhede, Mayur , Maraj, Adrian Matthew, Osborne, Wendy , Calvert, Victoria, El‐Sharkawi, Dima , Hilali, Ammar, Collins, Graham P., Elmusharaf, Nagah, Santarsieri, Anna , Karim, Farheen, Monick, Sarah, Trutzer, Iris Margalit, Can, Jones, Ayers, Amy , Feo, Jacopo Calabrese De, Ghosh, Nilanjan, Treitman, Rachel, Okcu, Izel, Hann, William D., Barrett, Aisling , Deshani, Vismay, Cwynarski, K., Wang, Yucai , Saha, Aditi , Ghione, Paola , Khwaja, Jahanzaib , Saha, Aditi , Wang, Yucai , Cherng, Hua-Jay J , Tolu, Seda , Wagner-Johnston, Nina , Ollila, Thomas A , Grover, Natalie S , Koff, Jean L , Ramakrishnan Geethakumari, Praveen , Sandoval-Sus, Jose , Epperla, Narendranath , Wallace, Danielle S , Kamdar, Manali , Tun, Han W , Narkhede, Mayur S , Rhodes, Joanna , Okosun, Jessica , El-Sharkawi, Dima , Collins, Graham P , Linton, Kim M , Santarsieri, Anna , Baidoun, Firas , Monick, Sarah E, Calabrese De Feo, Jacopo , Sharp, John , Ghosh, Nilanjan , Okcu, Izel , Hann, William , Barrett, Aisling , Deshani, Vismay , Kahl, Brad S , Chavez, Julio C , Olszewski, Adam J , Ghione, Paola , Dong, Ning, Wagner‐Johnston, Nina D. , Grover, Natalie S. , Koff, Jean L. , Epperla, Narendranath , Wallace, Danielle , Kamdar, Manali , Tun, Han W. , Muñoz, Javier, Rhodes, Joanna , Prica, Anca A. , Kühnl, Andrea , Maraj, Adrian , Smith, Jeff , Calvert, Victoria, Linton, Kim , Baidoun, Firas , Sharp, John , Kallam, Avyakta , Abeyakoon, Chathuri , Kahl, Brad S. , Olszewski, Adam J. , Cwynarski, Kate

Mayo Clinic

Blood | January 5, 2026 | Volume: 147 | Issue: 16 | Pages: 1814-1827

10.1182/blood.2025031455 | PMID 41490516 Get It

Abstract Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes after thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor (CAR) T-cell therapy (CAR-T) delivered at relapse were compared after propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). Two-year PFS estimates were 40.4%, 43.9%, and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse, respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR, 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: hazard ratio [HR], 0.57; P = .005; and OS: HR, 0.62; P = .023) and CNS-isolated relapses (PFS: HR, 0.55; P = .002; and OS: HR, 0.39; P&lt; .0001). ASCT (thiotepa or no thiotepa) also associated with improved survival in synchronous relapses (PFS: HR, 0.57; P = .023; and OS: HR, 0.48; P = .019). Higher survival with thiotepa-ASCT than CAR-T was observed after PSM (PFS: HR, 0.45; P = .005 and OS: HR, 0.41; P = .014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, C. R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Q., Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew , Whittington, Alex , Carrillo, Maria, Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, H., Stephenson, Diane , Tatton, Nadine , Brendel, M., Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald, Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Kolb, Hartmuth C. , Brendel, Matthias , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109722 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [¹⁸F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [¹⁸F]flortaucipir (ADNI), [¹⁸F]MK‐6240 (CPAS), and [¹⁸F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([¹⁸F]flortaucipir) and AIBL ([¹⁸F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [¹⁸F]flortaucipir and [¹⁸F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([¹⁸F]PI‐2620) are underway.
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
Torka, Pallawi , Bock, Allison M. , Vaughn, John, Thiruvengadam, Swetha, Sekaran, Kanithra , Lee, Calvin , Smilnak, Gordon , Patel, Vrutti , Baek, Grace , Mynam, Ritwick , Sano, Dahlia , Gerber, Drew, Palmeri, Marisa, Mrad, Rudy, Sharp, John , Geethakumari, Praveen Ramakrishnan , Karimi, Yasmin , Feldman, Tatyana , Svoboda, Jakub , Shanmugasundaram, Krithika , Herrera, Alex F. , Karimi, Yasmin H , Назаренко, Елена Борисовна , Xu, Yizhe , Vaughn, John, Thiruvengadam, Swetha, Major, Ajay , Reef, Daniel K. , Luttwak, Efrat , Shah, Harsh , Ip, Andrew , Falade, Ayo , Iqbal, Madiha , Voorhees, Timothy , Rhodes, Joanna , Durani, Urshila , Cherng, Hua‐Jay J. , Pophali, Priyanka A. , Di, Mengyang , Niu, Alex , Grover, Natalie S. , Karmali, Reem , Diefenbach, Catherine , Epperla, Narendranath

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3622-3622

10.1182/blood-2025-3622 Get It

Abstract Introduction: Older adults (OAs) with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients (pts). NAVD has been widely adopted in clinical practice for frontline (1L) treatment of OAs with advanced stage cHL based on the subset analysis of S1826 study (Rutherford et al, JCO 2025) showing a 1-year progression-free survival (PFS) of 93% and 1-year overall survival (OS) of 95% after NAVD (n = 50) which remained durable on longer-term follow up. Another phase 2 study (Torka et al, JCO 2025) showed that NAVD is a highly effective and well-tolerated 1L regimen in OAs with cHL (n=40) across a wide range of geriatric impairments. Adverse events (AEs) and efficacy have not been reported in OAs treated with NAVD outside of a clinical trial. Hence, we sought to evaluate safety profile and efficacy outcomes of OAs with cHL treated with 1L NAVD in a real-world setting (RWS). Methods This is a multicenter retrospective cohort study of adults (≥18 years) with cHL treated with 1L NAVD between 2023 and 2025 at 20 US academic sites. Baseline characteristics and outcomes of pts ≥60 years were evaluated as a pre-planned subset analysis. The safety evaluable cohort received at least 1 cycle of NAVD and included pts who had not yet completed treatment. The efficacy evaluable cohort had completed 6 cycles of treatment including end of treatment (EOT) PET-CT and included pts who intended to complete treatment but died or discontinued due to progressive disease or AEs. The primary endpoint was EOT overall response rate (ORR). Secondary endpoints included EOT complete response rate (CRR), PFS and OS. PFS and OS were analyzed using the Kaplan Meier method. Results Among 311 pts, 81 were OAs (26%). Median age of the OA cohort was 70 (range 60-88) yrs, 65% male, 84% Caucasian, 71% nodular sclerosis subtype, 58% stage 4 disease, 59% B symptoms, 14% bulky disease (&gt;7.5 cm), 69% extranodal sites, 41% EBV positive, 54% hypoalbuminemia, 49% IPS ≥ 4 and10% had an autoimmune disease. G-CSF was given in 81% pts. All 81 pts were evaluable for safety; 74% experienced a grade 3+ (≥G3) AE, 54% had ≥G3 hematological AE, 48% had ≥G3 neutropenia, 17% had febrile neutropenia. Infection rate was 28% with 10% ≥G3, neuropathy rate was 23% with 4% ≥G3. One infusion reaction was noted. Treatment related hospitalizations rate was 23% with median duration of 7 (range 1-16) days. There were 24 immune related AEs (IrAE) (30%) of which 5 were ≥G3. Most common IrAE was hypothyroidism (n=5), followed by inflammatory arthritis (n=4), pneumonitis (n=2, ≥G3, n=1), hepatitis (n=2, both ≥G3), adrenal insufficiency (n=2, ≥G3, n=1), colitis (n=2), and rash (n=2). One patient each had autoimmune neutropenia, sarcoidosis of lung/skin and myocarditis (≥G3). Overall, 15% pts required steroids with resolution of IrAEs in 56% cases, 30% (n=7) pts required continued therapy (levothyroxine in 4 pts, steroids in 3 pts, medical tx for heart failure in 1 pt). Treatment was interrupted in 22%, reduced in 22%, and discontinued in 23% pts. Nivolumab was discontinued in 14% pts. Among all pts (n=81), 81% had an interim PET-CT after 2-4 cycles. The ORR and CR rate at interim PET-CT were 100% and 81%, respectively. In the efficacy evaluable pts (n=52; 24 still on therapy), the EOT ORR and CRR were 93.2% and 84% in OAs compared to 96.8% and 91.7% in pts &lt;60yrs, respectively. At a median follow up of 10.2 mo (range 0.27-28.52), the 1-yr PFS was 90.6% (95% CI: 82.7%-99.3%) in OAs and 95.5% (95% CI: 91.6%- 99.6%) in pts &lt;60 yrs (p=0.044). 1-yr OS was 97.5% (95% CI: 94.1-100%) and not evaluable in pts &lt;60yrs (p=0.017). None of the baseline features were predictive of response, additional analysis to understand impact on AEs and survival is ongoing. Among the 5 pts with progression/relapse, 4 were primary refractory. 4 pts received 2nd line (2L) therapy.79 pts are alive at data cut off, 2 deaths occurred- 1 infection-related and other unknown; both after the 1st cycle. Conclusions In this largest RWS cohort of OAs treated with NAVD we showed comparable response rates, AEs and 1-year survival outcomes to those in the pivotal S1826 trial. Notably, rates of ≥G3 AEs including infections, neuropathy and IrAEs remained low and manageable. Although survival significantly improved with NAVD compared to historical data, outcomes of OAs remained inferior compared to pts &lt;60 yrs. Our data reinforces the use of NAVD as the preferred 1L option for OAs with advanced stage cHL.
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
Bock, Allison M. , Thiruvengadam, Swetha, Sano, Dahlia , Sekaran, Kanithra , Vaughn, John, Sharp, John , Patel, Vrutti , Araújo, Ney Soares de, Mynam, Ritwick , Smilnak, Gordon , Palmeri, Marisa, Abhyankar, Anuja , Gerber, Drew, Geethakumari, Praveen Ramakrishnan , Baek, Grace , Shanmugasundaram, Krithika , Feldman, Tatyana , Svoboda, Jakub , Karimi, Yasmin , Herrera, Alex F. , Torka, Pallawi , Karimi, Yasmin H , Luttwak, Efrat , Назаренко, Елена Борисовна , Xu, Yizhe , Thiruvengadam, Swetha, Vaughn, John, Reef, Daniel K. , Major, Ajay , Araujo, Nicole, Falade, Ayo , Iqbal, Madiha , Di, Mengyang , Hu, Boyu , Durani, Urshila , Cherng, Hua‐Jay J. , Niu, Alex , Rhodes, Joanna , Pophali, Priyanka A. , Voorhees, Timothy , Grover, Natalie S. , Diefenbach, Catherine , Karmali, Reem , Epperla, Narendranath

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1841-1841

10.1182/blood-2025-1841 Get It

Abstract Introduction: NAVD has become a standard-of-care for frontline (1L) treatment (tx) of advanced stage cHL, based on the results of the S1826 study. S1826 demonstrated a 1-year progression free survival (PFS) of 94% for NAVD compared to 86% for brentuximab vedotin-AVD, which remained durable at 2 years (Herrera et al, NEJM 2024). Adverse events (AEs) and efficacy have not been reported in patients (pts) treated with NAVD outside of a clinical trial. Hence, we sought to evaluate safety profile and efficacy outcomes of pts with cHL treated with 1L NAVD in a real-world setting (RWS). Methods: In this multicenter retrospective cohort study, we included pts ≥18 years with cHL treated with 1L standard of care NAVD between 2023 and 2025 at 20 US academic sites. The safety evaluable cohort received at least 1 cycle of NAVD and included pts who have not completed tx. The efficacy evaluable cohort had completed 6 cycles of tx including end of treatment (EOT) PET-CT and included pts who intended to complete tx but died or discontinued due to progressive disease or AEs. The primary endpoint was EOT overall response rate (ORR). Secondary endpoints included EOT complete response rate (CRR), PFS and overall survival (OS). PFS and OS were calculated from the start date of tx and analyzed using the Kaplan Meier method. Results: A total of 311 pts with cHL were treated with NAVD with 26% of pts with tx ongoing (n=83) and 73% with tx completed (n=228). Baseline demographics included 55% male pts, 60% with stage IV disease (stage IIB, n=4) and 84% with nodular sclerosis subtype. Median age was 37 years (range 18-88), 29% had bulky disease (&gt;7.5 cm), 28% were EBV positive (n=74/268), 8% had history of an autoimmune disease, and 31% had an IPS 4-7. G-CSF was given in 64% of pts. All patients were safety evaluable. Tx was interrupted (any length) in 24%, reduced in 12%, and discontinued in 14%. The most common reason for dose reduction was neuropathy in 4%. Nivolumab was discontinued in 10% and all therapy in 3.7% due to toxicity. Any AE and any grade 3 or higher AE (&gt;G3) were observed in 92% and 62%, respectively. Neutropenia of any grade occurred in 68% (48% &gt;G3), infection in 25% (10% &gt;G3), and neuropathy in 30% (2.8% &gt;G3). Hospitalization for an AE occurred in 20% (4.5% febrile neutropenia). Among pts with complete data (n=305), any immune related AE (irAE) occurred in 78 pts (25.6%) with any &gt;G3 irAE in 23 pts (7.5%). The most common irAEs included hypothyroidism (7.9%, all grade 1-2), hepatotoxicity (1.6% G1/G2, 3.3% &gt;G3), inflammatory arthritis (3% G1/G2, 0.6% &gt;G3), rash (2.6%, all grade 1-2), and colitis (1% G1/G2, 1% &gt;G3). Other notable &gt;G3 irAEs included adrenal insufficiency (n=2), AKI/ATN (n=1), myocarditis (n=1), diabetes (n=1) and pancreatitis (n=1). Of 84 irAE events, 47 (56%) have had complete resolution. Among all pts, 14.4% (n=45) required systemic steroids at any time (intravenous in 4.1%), 3.2% (n=10) require ongoing steroids/immunosuppression and 8.3% other therapy for an irAE (n=23 levothyroxine, n=1 hemodialysis, n=1 heart failure tx, n=1 insulin). Among all pts, 265 (85%) had an interim PET-CT after 2-4 cycles. The ORR and CRR at interim PET-CT were 97% and 78%, respectively. In the efficacy evaluable population (n=228), the EOT ORR and CRR were 96% and 90%. The median follow up was 10.2 mo (range 0.27-28.52). The 1-year PFS and OS estimates were 93.8% (95% CI: 90.8-98.4%) and 99.1% (95% CI: 97.9-100%), respectively. In multivariable analysis (MVA), only IPS score (OR 0.6, 95%CI: 0.59-0.60) was associated with lower CRR. In Cox univariable analysis, EBV+ status (HR=14.8, 95% CI: 3.2-69.2), IPS score (HR=1.5, 95% CI: 1.0-2.2), and ESR (HR=1.02, 95% CI: 1.00-1.04) were associated with worse PFS. Among the 11 pts with progression/relapse, 9 were primary refractory. 10 pts were started on second line (2L) therapy, and all pts are alive (1 pt pending 2L tx initiation). There were 2 deaths: one related to infectious complications and other unknown and both occurred after the first cycle of therapy. Conclusions: Pts treated with NAVD in a large RWS showed comparable response rates and 1-year survival outcomes to those in the pivotal S1826 trial. Most AEs were similar and grade 1-2, but close monitoring of irAEs is necessary given the potential long-term toxicity of checkpoint inhibitors and potential for ≥G3 irAEs (7.5%) in this young patient population. Our data supports the use of NAVD for 1L advanced stage cHL.
Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Abbott, Diana, Amorim, Ana , Houshyar, Samin , Adhikari, Arjab, Patel, Dilan A. , Wanjiku, Christopher, Bock, Allison M. , Any, Haya Al, Desai, Nidhi , Gupta, S. C. , Altomare, Nicole , Trotier, Daniel, Ricker, Edd , Hill, Brian T. , Gupta, Supriya , Major, Ajay , Abbott, Diana , Snyder, Jordan Andrew , Ahmed, Nausheen , Villasboas, José C. , Sharp, John, Voorhees, Timothy , Wallace, Danielle, Wagner, Charlotte B , Brooks, Taylor , Tsang, Mazie , Rajab, Mohamed , Iqbal, Madiha , Gupta, Supriya, Karmali, Reem , Pophali, Priyanka A. , Cherng, Hua‐Jay J. , Gupta, Arjun

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1798-1798

10.1182/blood-2025-1798 Get It

Abstract Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractory (R/R) follicular lymphoma (FL), but differ in treatment schedules and associated “time toxicity,” or contact days spent physically interacting with the healthcare system. While contact days can be estimated from clinical trials, real-world data provides a more nuanced depiction of treatment-related time burden, which may guide treatment decision-making. The comparative time toxicity of CAR-T vs BsAb in R/R FL is not defined. Methods We conducted a multicenter retrospective study of adults with R/R grade 1-3A FL who received standard-of-care CAR-T (axi-cel, tisa-cel, liso-cel) or BsAb (mosunetuzumab, epcoritamab) in the third-line or later setting before Jan 1, 2025. Time toxicity was defined as outpatient or inpatient days with physical health care system contact, counting multiple visits on the same day as only one day. All days after treatment initiation were counted, regardless of disease progression, therapy completion, or relation to FL therapy. Median contact days over 1-year time horizon were compared, stratified by CAR-T vs BsAb, prior lines of therapy (LOT, 2 vs 3+), and time intervals (0-1, 1-3, 3-6, 6-9, and 9-12 months). Progression-free survival (PFS) and overall survival (OS) were calculated from day of CAR-T infusion or day 1, cycle 1 for BsAb. Cox regression and propensity matching (by age, ECOG, refractory to prior LOT, POD24) were used to assess predictors and survival associations with contact days. Results Among 209 patients from 15 U.S. academic centers, median age was 64, 37% were female, 61% received CAR-T (80% axi-cel, 7% liso-cel, 13% tisa-cel) and 39% BsAb (93% mosun, 7% epcor). Most had Grade 1-2 FL (72%), advanced stage (84%), and extranodal disease (51%). Median prior LOT was 3 (range 2-15), 41% were refractory to prior LOT, and 52% had POD24. Median number of BsAb doses was 10 (range 1-36). Patients receiving BsAb were significantly older (p&lt;.01) and had higher CIRS comorbidity scores (p&lt;.02) in both 2 and 3+ prior LOT cohorts, and had higher ECOG scores (p=.01) and were less likely to be refractory to prior LOT (p=.029) in 3+ LOT cohort. There were no differences in POD24 rates between CAR-T and BsAb. Median PFS for the entire cohort was 3.6 yrs; median OS was not reached. In the 2 prior LOT cohort (N=75), 60% received CAR-T and 40% BsAb. With median follow-up of 1.5 years, median PFS was not reached for CAR-T and 1.6 yrs for BsAb (p&lt;.0001). In the 3+ prior LOT cohort (N=134), 62% received CAR-T and 38% BsAb. With median follow-up of 2 yrs, median PFS was 3.6 yrs for CAR-T and 1.6 yrs for BsAb (p=.0044). In propensity matched analysis, PFS was shorter for BsAb in both 2 LOT (HR 9.0, 95% CI 1.14-71.04, p=.037) and 3+ LOT (HR 3.25, 95% CI 1.06-9.97, p=.039) cohorts as compared to CAR-T. There were no significant differences in OS between CAR-T and BsAb. Median contact days were significantly higher for CAR-T vs BsAb in the 0-1 month interval: 19 vs 8 days in 2 LOT (p&lt;.0001) and 18 vs 7 days in 3+ LOT (p&lt;.0001) cohorts. There were no differences in contact days between CAR-T vs BsAb in subsequent time intervals. Over 1 year, CAR-T had significantly more time toxicity than BsAb: median 51 vs 36 contact days in 2 LOT (p&lt;.0001) and 64 vs 38 days in 3L+ LOT (p&lt;.0001) cohorts; these remained significant in the matched analysis. B symptoms (p=.04) and Grade ≥3 cytopenias (p=.007) were associated with higher contact days in 3+ LOT cohort in univariable analysis. Higher contact days were associated with inferior PFS (HR 1.01, 95% CI 1.00-1.02, p=.032) and OS (HR 1.01, 95% CI 1.00-1.02, p=.038) in 3+ LOT cohort regardless of treatment type. Discussion In this large real-world cohort of patients with R/R FL, CAR-T therapy resulted in better PFS but more time toxicity over the first year as compared to BsAb therapy. Excess time toxicity from CAR-T was driven by more contact days in the first month of treatment. This study provides benchmark data for counseling patients about expected time burden of CAR-T (51-64 days) and BsAb (36-38 days) over the first year of these therapies. Further, with superior PFS of CAR-T in this study and minimal impact of time toxicity on survival outcomes, these data can be used to better support shared decision-making in R/R FL by addressing patient preferences regarding both contact days as well as duration of disease control.
Genetic Testing in the Management of Adult CKD
Chebib, Fouad T. , Wang, Xiangling , Udani, Suneel M. , Westemeyer, Maggie , Clark, Dinah, Zhang, Zhiji, Rasouly, Hila Milo , Kolupaeva, Victoria, Mizani, Mohammad R. , Faravardeh, Arman , Kotte, Sri, Punj, Sumit , Chapman, Steven L. , Schneider, Ronen, Tabriziani, Hossein , Bhorade, Sangeeta , Gharavi, Ali G. , Kolupaeva, Victoria , Bloom, Michelle S , Milo Rasouly, Hila , Mizani, Mohammad R , Dossabhoy, Neville R , Faravardeh, Arman , Demko, Zachary P , Punj, Sumit , Chapman, Steven L , Rabinowitz, Matthew , Tabriziani, Hossein , Bhorade, Sangeeta , Dahl, Neera K , Westemeyer, Maggie , Kolupaeva, Victoria , Chebib, Fouad T , Wang, Xiangling , Udani, Suneel M. , Clark, Dinah, Zhang, Zhiji, Kotte, Sri, Schneider, Ronen, Gharavi, Ali G.

Mayo Clinic

Journal of the American Society of Nephrology | December 3, 2025 | Volume: 37 | Issue: 4 | Pages: 777-789

10.1681/asn.0000000913 | PMID 41563380 Get It

Key Points Genetic testing in CKD showed diagnostic and clinical utility in the year following reporting of test results. Genetic testing was helpful for or changed management in 86% of patients with a positive finding and 42% with a negative finding. Clinical utility was seen across 12 clinical cohorts, including CKD of unknown etiology and hypertension or diabetes-related nephropathy. Background CKD is a significant public health burden, affecting >800 million people worldwide with significant cost to the health care system. CKD is a disease process with substantial genetic and phenotypic heterogeneity that can obscure a definitive diagnosis, resulting in suboptimal management. Recent guidelines support greater adoption of genetic testing in CKD. We assessed the diagnostic and clinical utility in the year following broad-panel CKD genetic testing. Methods The Renasight Clinical Application, Review, and Evaluation (RenaCARE) study (NCT05846113) was a single-arm, interventional, prospective, multicenter study evaluating the utility of genetic testing with a 385-gene panel on the diagnosis and management of CKD. Clinical history was collected before testing, and nephrologists responded to questionnaires at both 1 month and 1 year after testing. The impact of genetic testing on CKD diagnosis and management were assessed in active study patients at the 1-year time point. Results In a cohort of 1388 CKD patients with 13 pretest clinical categories of CKD, 335 (24%) patients had a positive genetic finding; 1174 had a questionnaire completed at 1 year and were included in the analysis. Genetic testing was reported helpful for clinical management and/or led to a change in management in 86% of patients with a positive test finding and 42% of patients with a negative test finding. In addition, genetic testing resulted in a change in the physician estimation of the 5-year prognosis for 55% of patients with a positive test finding and 18% of those with a negative test finding. Conclusions Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.
Nuclear DAB2IP regulates DNA replication initiation through activating PLK1-mediated HBO1 phosphorylation
Shang, Zeng‐Fu , Yu, Lan , Newman, Ciara , Chen, Wei‐Min , Birdsong, Grant W, Sharp, Brett C, Story, Michael D. , Saha, Debabrata , Davis, Anthony J. , Davis, Anthony J , Saha, Debabrata

Mayo Clinic

Nucleic Acids Research | November 20, 2025 | Volume: 53 | Issue: 21 | Pages: No page available

10.1093/nar/gkaf1179 | PMID 41261855 Get It

Abstract DAB2IP (Disabled homolog 2 interacting protein), a recognized tumor suppressor, plays a pivotal role in regulating various oncogenic pathways. Our previous research demonstrated that DAB2IP functions as a cell cycle regulator by facilitating PLK1-mediated mitosis progression. Here, we elucidate a novel function of DAB2IP in promoting DNA replication origin firing. Mechanistically, we identified that DAB2IP localizes to the nucleus, where it interacts with the histone acetyltransferase HBO1 and enhances the HBO1–PLK1 interaction. DAB2IP facilitates PLK1-mediated phosphorylation of HBO1, which subsequently promotes HBO1-directed acetylation of histone 3 at lysine 14 (H3K14Ac). This modification enables the loading of the minichromosome maintenance protein (MCM) complex onto chromatin, thereby supporting DNA replication and maintaining genome integrity. Additionally, we found that ATR regulates CDK1-mediated phosphorylation of DAB2IP, and that this phosphorylation is essential for the formation and activation of the HBO1-PLK1 complex. Ablation of DAB2IP phosphorylation results in increased genomic instability due to incomplete replication of genomic DNA, as evidenced by the accumulation of anaphase ultrafine bridges and 53BP1 nuclear bodies in G1 phase of the cell cycle. In summary, our findings underscore the critical regulatory role of DAB2IP in DNA replication initiation and genomic stability maintenance, providing new insights into its function in cellular homeostasis.